Financial Data and Key Metrics Changes - Net income for the first quarter was $18.7 million compared to a net loss of $5.6 million last year [7] - EBITDA increased to $91.9 million from $56.9 million year over year [7] - Adjusted EBITDA rose to $91.1 million from $56 million in the prior year [8] - Distributable cash flow was $45.7 million compared to $15.8 million last year, with adjusted DCF at $46.4 million versus $16 million [8] - TTM distribution coverage as of March 31, 2025, was 2.03x or 1.96x after factoring in distributions to preferred unitholders [9] Business Line Data and Key Metrics Changes - GDSO product margin increased by $200,000 to $187.9 million [10] - Gasoline distribution product margin rose by $4.2 million to $125.8 million, reflecting higher fuel margins [10] - Station operations product margin decreased by $4 million to $62.1 million due to sales and conversions of certain company-operated sites [10] - Wholesale segment product margin increased by $44.2 million to $93.6 million, driven by favorable market conditions [11] - Product margin from gasoline and gasoline blend stocks increased by $27.4 million to $57.1 million [11] - Product margin from distillates and other oils increased by $16.8 million to $36.5 million, aided by colder winter weather [12] Market Data and Key Metrics Changes - The first quarter experienced a 9% colder winter compared to the prior year, positively impacting the wholesale distillate business [21] - A brief period of tariffs on Canadian oil created volatility, benefiting the company, although the impact was short-lived [24] Company Strategy and Development Direction - The company is focused on optimizing terminal assets and expanding its midstream footprint to better serve customers [5] - Ongoing portfolio optimization has led to a decrease in company-operated sites, aligning with strategic goals [10] - The company aims to maintain financial discipline while pursuing organic growth and selective acquisitions [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and commitment to long-term growth for unitholders [14] - The integration of terminal assets has enhanced capacity and market opportunities [21] - Management noted that the current operating environment is dynamic, with ongoing reviews of retail business assets [18] Other Important Information - The Board increased the quarterly cash distribution on common units to $0.07 per unit, equating to $2.98 on an annualized basis [6] - The company will participate in several upcoming investor conferences [13] Q&A Session Summary Question: Opportunities in terminal acquisitions and capital repositioning - Management is continuously reviewing retail business assets and is opportunistic in capital allocation, focusing on competitive advantages and higher returns [18][20] Question: Market conditions contributing to wholesale performance - A colder winter and the integration of terminal assets contributed to strong wholesale performance, with a normalized quarter compared to the previous year [21][22] Question: Impact of tariffs on market conditions - A brief period of tariffs created volatility but had no significant ongoing impact on supply or margins; potential consumer impact on store sales is yet to be determined [24][25]

Financial Data and Key Metrics Changes - Net income for Q1 2025 was $18.7 million compared to a net loss of $5.6 million in Q1 2024 [7] - EBITDA increased to $91.9 million from $56.9 million year over year [7] - Adjusted EBITDA rose to $91.1 million from $56 million in the prior year [7] - Distributable cash flow (DCF) was $45.7 million in Q1 2025, up from $15.8 million in the prior year [7] - Adjusted DCF increased to $46.4 million compared to $16 million last year [7] - TTM distribution coverage as of March 31, 2025, was 2.03x, or 1.96x after factoring in distributions to preferred unitholders [9] Business Line Data and Key Metrics Changes - GDSO product margin increased by $200,000 to $187.9 million in the quarter [10] - Gasoline distribution product margin rose by $4.2 million to $125.8 million, reflecting higher fuel margins [10] - Station operations product margin decreased by $4 million to $62.1 million due to sales and conversions of certain company-operated sites [10] - Wholesale segment product margin increased by $44.2 million to $93.6 million, driven by favorable market conditions [11] - Product margin from gasoline and gasoline blend stocks increased by $27.4 million to $57.1 million [11] - Product margin from distillates and other oils rose by $16.8 million to $36.5 million, aided by colder winter weather [12] Market Data and Key Metrics Changes - The Northeast experienced a colder winter, which positively impacted the wholesale distillate business [20] - Market conditions were favorable due to the integration of terminal assets, allowing the company to capitalize on market opportunities [20] - A brief period of tariffs on Canadian oil created volatility that benefited the company, although it was short-lived [23] Company Strategy and Development Direction - The company is focused on optimizing terminal assets and maintaining financial discipline while pursuing organic growth and selective acquisitions [6] - The strategy includes continuous review of retail business and assets to maximize operational efficiency [18] - The company aims to leverage its scale and integrated model to navigate disruptions and find opportunities [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and commitment to delivering long-term growth for unitholders [14] - The company is optimistic about its ability to adapt to market conditions and capitalize on opportunities as they arise [14] Other Important Information - The Board increased the quarterly cash distribution on common units to $0.07 per unit, equating to $2.98 on an annualized basis [6] - Upcoming participation in several investor conferences was announced, including the EIC's Annual Energy Infrastructure Investor Conference [13] Q&A Session Summary Question: Discussion on GDSO and terminal opportunities - Management indicated ongoing reviews of retail business and asset optimization, emphasizing opportunistic approaches to acquisitions [18] Question: Market conditions contributing to wholesale performance - Management noted favorable market conditions, including a colder winter and the integration of terminal assets, which enhanced capacity and market opportunities [20] Question: Impact of tariffs on market conditions - Management clarified that the impact of tariffs was brief and did not significantly affect supply or margins, though it may influence store sales in the future [23]

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Gregory B. Hanson Sean T. Geary Global Partners LP Global Partners LP (781) 894-8800 (781) 894-8800 Chief Financial Officer Chief Legal Officer and Secretary Global Partners LP Reports First-Quarter 2025 Financial Results Waltham, Mass., May 8, 2025 – Global Partners LP (NYSE: GLP) today reported financial results for the first quarter ended March 31, 2025. CEO Commentary "Global delivered solid first-quarter results, highlighting the strength of our integrated a ...

Core Viewpoint - Vivani Medical, Inc. is advancing its miniature, ultra long-acting drug implants aimed at improving patient adherence in chronic disease treatment, particularly in the GLP-1 drug class [1][4][5] Company Overview - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic implants using its proprietary NanoPortal™ technology [4] - The company’s lead programs include NPM-115 (exenatide implant) and NPM-139 (semaglutide implant), designed for chronic weight management with administration once or twice a year [4] - Vivani is also developing NPM-119, a six-month GLP-1 implant for type 2 diabetes treatment [4] Upcoming Events - CEO Adam Mendelsohn will present on "Addressing Patient Adherence: Advances in Drug Delivery" at the AAPS workshop on May 14, 2025 [2] - A panel discussion featuring Dr. Mendelsohn will address key hurdles and trends in GLP-1 drug development on the same day [3] Market Context - Medication non-adherence affects approximately 50% of patients, contributing to over $500 billion in annual avoidable healthcare costs and 125,000 preventable deaths in the U.S. [5] - The current GLP-1 landscape includes over 50 new molecular entities in clinical development, positioning Vivani's differentiated portfolio as a potential attractive option for patients and healthcare providers [5]

Core Viewpoint - Cencora (COR) is expected to report second-quarter fiscal 2025 results on May 7, with anticipated revenue of $74.82 billion, reflecting a 9.4% year-over-year increase, and earnings per share of $4.08, indicating a 7.4% improvement from the prior year [1][2] Group 1: Financial Performance - Cencora's U.S. Healthcare Solutions segment is projected to have achieved 14% revenue growth to $74 billion and a 10% increase in segment operating income, driven by strong demand for specialty distribution and GLP-1 drugs [2][3] - The company is expected to report revenues of $66.61 billion for the GLP-1 drug segment, with adjusted operating income estimated at $901.9 million [4][7] - The international Healthcare Solutions segment is anticipated to show 5.5% revenue growth, but a 3% decrease in reported operating income, primarily due to a stronger U.S. dollar affecting reported growth [5] Group 2: Market Dynamics - Cencora's strong distribution execution and the growing adoption of biosimilars position the company for consistent revenue performance [3] - The company faces challenges from declining COVID-19 vaccine contributions, which may negatively impact segment sales and margins [4] - A continuation of softer performance in specialty logistics, particularly World Courier, is expected due to muted activity in clinical trials and cell and gene therapies [6] Group 3: Earnings Expectations - The model predicts an earnings beat for Cencora, supported by a positive Earnings ESP of +0.82% and a Zacks Rank of 2 (Buy) [8][9]

Core Insights - iBio, Inc. announced promising preclinical data for its Activin E antibody, showing a 26% reduction in fat mass in diet-induced obese mice while preserving muscle mass [1][6] - The study demonstrated significant reductions in specific fat depots, with a 31% reduction in subcutaneous fat and reductions of 34% and 37% in epididymal and retroperitoneal fat, respectively [3][6] - When combined with a GLP-1 receptor agonist, the Activin E antibody resulted in a total fat mass reduction of 77%, indicating strong synergistic effects [3][6] Company Overview - iBio, Inc. is a biotech company focused on developing biopharmaceuticals for cardiometabolic diseases, obesity, and cancer using AI and advanced computational biology [4] - The company aims to transform drug discovery and accelerate development timelines through innovative drug discovery platforms and proprietary 3D modeling [4]

Novo Nordisk A/S NVO announced that CVS Health Inc’s CVS CVS Caremark, a Pharmacy Benefit Manager (PBM), has decided that Wegovy (semaglutide) injection 2.4 mg will soon be the preferred GLP-1 medicine on its largest commercial template formularies.This change will take effect on July 1, 2025. “We believe in the unique benefits of Wegovy and the difference this medicine can make for patients seeking treatment,” said Dave Moore, executive vice president of U.S. Operations and president of Novo Nordisk Inc.In ...

Core Viewpoint - The article discusses the potential for investing in undervalued stocks that are mispriced by the market, particularly focusing on the company HIMS and its stock performance. Group 1: Investment Opportunities - The article suggests that there may be beneficial long positions available in HIMS through stock purchases or call options within the next 72 hours [2]. - It emphasizes the importance of conducting personal research before making investment decisions, highlighting that past performance does not guarantee future results [4]. Group 2: Market Positioning - The article encourages investors to consider joining platforms like Out Fox The Street for insights on positioning in undervalued stocks [1]. - It notes that the opinions expressed are those of the author and may not reflect broader market views, indicating a level of independence in the analysis [4].

Financial Data and Key Metrics Changes - Adjusted EBITDA for Q4 2024 was $97.8 million, down from $112.1 million in Q4 2023, reflecting a challenging fuel margin environment [16] - Adjusted DCF decreased to $46.1 million from $58.8 million year-over-year [16] - Trailing twelve-month distribution coverage was 1.81 times, or 1.72 times after preferred unitholder distributions [17] Business Line Data and Key Metrics Changes - GDSO product margin decreased by $31.8 million to $213.6 million in Q4 2024, with gasoline distribution product margin down $32.1 million to $145.7 million due to lower fuel margins [17][18] - Fuel margins on a cents per gallon basis decreased from $0.44 in Q4 2023 to $0.36 in Q4 2024 [18] - Station operations product margin increased by $0.3 million to $67.9 million in Q4 2024, with a total of 1,584 fueling stations and convenience stores in the GDSO portfolio [20] Market Data and Key Metrics Changes - Wholesale segment product margin increased by $27.9 million to $79.8 million in Q4 2024, driven by favorable market conditions and the acquisition of terminals from Motiva [21] - Product margin from gasoline and gasoline blend stocks increased by $13.2 million to $38.6 million [21] Company Strategy and Development Direction - The company integrated thirty new terminals, doubling storage capacity to approximately 22 million barrels, with significant investments totaling over $528 million [7][8] - The company is focused on leveraging its expanded operating footprint and strong balance sheet to seize growth opportunities [14] - Management emphasized the flexibility of their terminal facilities to source products from various regions, mitigating risks associated with potential tariffs [39][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the dynamic energy landscape and maintain operational excellence despite challenges [9][10] - The company anticipates 2025 to be a year of opportunity and growth, continuing to integrate recently acquired assets [26][27] Other Important Information - The board declared a distribution of $0.74 per common unit for Q4 2024, marking the thirteenth consecutive quarterly increase [13] - Operating expenses increased by $12.1 million due to the addition of new terminals, while SG&A expenses decreased by $1.9 million [22] Q&A Session Summary Question: What percentage of supply comes from outside the US? - Management indicated that while they cannot disclose exact percentages for competitive reasons, Canadian barrels are significant for the Northeast supply landscape [31][32] Question: How do tariffs affect acquisition plans? - Management stated that tariffs do not change their acquisition strategy, as their terminals are flexible and can source products from various locations [38][39] Question: What are the growth plans for Houston? - Management highlighted plans to grow retail, terminal, and wholesale operations in Houston, focusing on disciplined acquisitions and organic growth [44][48] Question: Any changes in acquisition opportunities or pricing? - Management noted that the market remains active with various opportunities, and they are hopeful for transactions in the coming year [51][52]

The CNN Money Fear and Greed index showed further decline in the overall market sentiment, while the index remained in the “Extreme Fear” zone on Thursday.U.S. stocks settled lower on Thursday, with the Nasdaq Composite dipping more than 500 points during the session.Nvidia Corp. NVDA shares plunged more than 8% on Thursday after the company released fourth-quarter results.On the economic data front, the second estimate released Thursday by the U.S. Bureau of Economic Analysis revised fourth quarter 2024 re ...